SCHEMBL19604352

SCHEMBL19604352

CC(C)(C)OCc1ccc(C(=O)c2ccccc2)c(N)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
GAA P10253 2/20 0.47
MAPK1 P28482 3/20 0.43
HTT P42858 3/20 0.43
ALDH1A1 P00352 3/20 0.43
LMNA P02545 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
HPGD P15428 2/20 0.43
PGR P06401 1/20 0.43
CYP2D6 P10635 1/20 0.43
SLC6A2 P23975 1/20 0.43
PDE4A P27815 1/20 0.43
HRH1 P35367 1/20 0.43
SLC6A3 Q01959 1/20 0.43
PDE4D Q08499 1/20 0.43
POLB P06746 1/20 0.42
ELANE P08246 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19604353 0.81 ESRRB (0.39) MAPTGAAMAPK1HTTALDH1A1
SCHEMBL10372217 0.80 MAPT (0.56) MAPTGAAMAPK1HTTALDH1A1
SCHEMBL18213792 0.79 PPARG (0.57) MAPTGAAHTTALDH1A1CYP2C19
SCHEMBL18177030 0.76 MAPT (0.51) MAPTGAAMAPK1HTTALDH1A1
SCHEMBL11351801 0.75 PLA2G2A (0.56) MAPTGAAALDH1A1LMNAPOLB
SCHEMBL11358202 0.74 MAPT (0.51) MAPTGAAMAPK1ALDH1A1LMNA
SCHEMBL8668315 0.73 PPARA (0.55) MAPTGAAALDH1A1MEN1KMT2A
SCHEMBL8497328 0.73 MEN1 (0.68) MAPTGAAMAPK1HTTALDH1A1
SCHEMBL21015601 0.72 MRGPRX4 (0.57) ALDH1A1NPSR1SMN1; SMN2
SCHEMBL20976415 0.72 MAPT (0.46) MAPTGAAMAPK1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170326250-A1 CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF NOVARTIS AG (CH) 2017-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170326250-A1 CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF MKI67, CCNI, PA2G4 MAPT 2692/4885GAA 240/4885MAPK1 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.